A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors.

Trial Profile

A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2014

At a glance

  • Drugs AVN 944 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 10 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top